文献速递浆细胞疾病

优化不适合移植的新诊断多发性骨髓瘤患者诱导和维持治疗中免疫调节药物的价值:Myeloma XI 多中心、开放标签、随机 III 期试验结果

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
PubMed 文献 · Br J Haematol · 2020-07-12

Myeloma XI 研究在不适合移植的新诊断多发性骨髓瘤患者中比较环磷酰胺联合沙利度胺和地塞米松(CTDa)与环磷酰胺联合来那度胺和地塞米松(CRDa)诱导治疗,随后随机分为来那度胺持续治疗或观察。CRDa 加深缓解但未改善无进展生存(PFS)或总生存(OS);≤70 岁患者中 CRDa 较 CTDs 见更深缓解及 PFS 和 OS 获益,老年患者毒性和停药增加。

要点

  • CRDa 较 CTDa 加深缓解,但未改善 PFS 或 OS。
  • ≤70 岁患者中 CRDa 较 CTDs 见更深缓解及 PFS 和 OS 获益。
  • 老年、衰弱患者中毒性和停药增加,可能限制治疗实施并影响结局。

核心结论

  • CRDa 加深缓解但未改善 PFS 或 OS;≤70 岁患者中 CRDa 较 CTDs 见更深缓解及 PFS 和 OS 获益,老年患者毒性和停药增加。
  • 结果强调在不适合移植的新诊断多发性骨髓瘤治疗中考虑年龄和衰弱的重要性,并指出需前瞻性验证衰弱适配的治疗方法。

研究设计与样本

  • Myeloma XI 为多中心、开放标签、随机 III 期试验,在不适合移植的新诊断多发性骨髓瘤患者中比较 CTDa 与 CRDa 诱导治疗,随后随机分为来那度胺持续治疗或观察。

主要发现

  • CRDa 较 CTDa 加深缓解,但未改善 PFS 或 OS。
  • ≤70 岁患者中 CRDa 较 CTDs 见更深缓解及 PFS 和 OS 获益。
  • 老年患者中观察到毒性和停药增加。

临床怎么用

  • 作者指出需前瞻性验证衰弱适配的治疗方法,可能通过个体化治疗改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed transplant-ineligible myeloma (ND-TNE-MM) has not been defined. The most appropriate delivery and dosing regimens of these therapies for patients at advanced age and frailty status is also unclear. The Myeloma XI study compared cyclophosphamide, thalidomide and dexamethasone (CTDa) to cyclophosphamide, lenalidomide and dexamethasone (CRDa) as induction therapy, followed by a maintenance randomisation between ongoing therapy with lenalidomide or observation for patients with ND-TNE-MM. CRDa deepened response but did not improve progression-free (PFS) or overall survival (OS) compared to CTDa. However, analysis by age group highlighted significant differences in tolerability in older, frailer patients that may have limited treatment delivery and impacted outcome. Deeper responses and PFS and OS benefits with CRDa over CTDs were seen in patients aged ≤70 years, with an increase in toxicity and discontinuation observed in older patients. Our results highlight the importance of considering age and frailty in the approach to therapy for patients with ND-TNE-MM, highlighting the need for prospective validation of frailty adapted therapy approaches, which may improve outcomes by tailoring treatment to the individual.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jackson GH, Pawlyn C, Cairns DA, et al. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br J Haematol. 2020. PMID: 32656799. doi:10.1111/bjh.16945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。